Intersect ENT, Inc. (NASDAQ:XENT) has earned an average rating of “Buy” from the twelve research firms that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have issued a hold recommendation and seven have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $18.57.

A number of equities research analysts have commented on the stock. Zacks Investment Research downgraded shares of Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. ValuEngine raised shares of Intersect ENT from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Northland Securities downgraded shares of Intersect ENT from an “outperform” rating to a “market perform” rating in a research report on Wednesday, May 31st. Canaccord Genuity reissued a “buy” rating on shares of Intersect ENT in a research report on Wednesday, May 3rd. Finally, William Blair reissued an “outperform” rating on shares of Intersect ENT in a research report on Wednesday, May 10th.

In other Intersect ENT news, CFO Jeryl L. Hilleman sold 12,835 shares of the firm’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $27.18, for a total transaction of $348,855.30. Following the completion of the transaction, the chief financial officer now directly owns 27,835 shares in the company, valued at approximately $756,555.30. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Lisa D. Earnhardt sold 20,000 shares of the firm’s stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $22.98, for a total transaction of $459,600.00. Following the transaction, the insider now owns 600,868 shares of the company’s stock, valued at $13,807,946.64. The disclosure for this sale can be found here. Insiders sold a total of 92,835 shares of company stock valued at $2,368,455 in the last quarter. Insiders own 13.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of the stock. American International Group Inc. increased its position in Intersect ENT by 7.1% in the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after buying an additional 1,037 shares during the period. Blair William & Co. IL increased its position in Intersect ENT by 32.4% in the first quarter. Blair William & Co. IL now owns 39,900 shares of the medical equipment provider’s stock valued at $543,000 after buying an additional 9,756 shares during the period. TFS Capital LLC increased its position in Intersect ENT by 74.9% in the first quarter. TFS Capital LLC now owns 51,426 shares of the medical equipment provider’s stock valued at $882,000 after buying an additional 22,024 shares during the period. Bank of New York Mellon Corp increased its position in Intersect ENT by 10.8% in the first quarter. Bank of New York Mellon Corp now owns 150,540 shares of the medical equipment provider’s stock valued at $2,582,000 after buying an additional 14,659 shares during the period. Finally, C WorldWide Group Holding A S increased its position in Intersect ENT by 10.0% in the first quarter. C WorldWide Group Holding A S now owns 181,550 shares of the medical equipment provider’s stock valued at $3,114,000 after buying an additional 16,550 shares during the period. Hedge funds and other institutional investors own 76.12% of the company’s stock.

Shares of Intersect ENT (NASDAQ:XENT) traded up 1.25% during trading on Monday, reaching $28.25. 90,187 shares of the company traded hands. The company’s market capitalization is $812.81 million. The firm’s 50 day moving average price is $27.22 and its 200-day moving average price is $19.28. Intersect ENT has a 52 week low of $7.65 and a 52 week high of $29.55.

Intersect ENT (NASDAQ:XENT) last announced its quarterly earnings data on Tuesday, May 2nd. The medical equipment provider reported ($0.23) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.25) by $0.02. Intersect ENT had a negative net margin of 28.71% and a negative return on equity of 20.49%. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $19.39 million. Equities analysts anticipate that Intersect ENT will post ($0.74) EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/07/24/intersect-ent-inc-nasdaqxent-given-average-rating-of-buy-by-brokerages.html.

Intersect ENT Company Profile

Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.

Analyst Recommendations for Intersect ENT (NASDAQ:XENT)

Receive News & Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related companies with MarketBeat.com's FREE daily email newsletter.